D. E. Shaw & Co. Inc. Sells 55,990 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

D. E. Shaw & Co. Inc. decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 42.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,476 shares of the company's stock after selling 55,990 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.12% of Vera Therapeutics worth $3,150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Huntington National Bank purchased a new stake in shares of Vera Therapeutics during the 4th quarter valued at about $26,000. AlphaQuest LLC bought a new stake in Vera Therapeutics during the fourth quarter worth approximately $34,000. KBC Group NV raised its position in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after purchasing an additional 1,387 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Vera Therapeutics by 16.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares during the last quarter. Finally, Moors & Cabot Inc. bought a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $220,000. Institutional investors own 99.21% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on VERA shares. Cantor Fitzgerald cut their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright initiated coverage on shares of Vera Therapeutics in a report on Monday, May 5th. They issued a "buy" rating and a $75.00 target price for the company. Guggenheim lifted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Finally, Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $63.33.

Vera Therapeutics Trading Down 3.7%

Shares of NASDAQ VERA traded down $0.76 during mid-day trading on Thursday, reaching $19.63. The company had a trading volume of 658,402 shares, compared to its average volume of 781,678. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -7.52 and a beta of 1.28. Vera Therapeutics, Inc. has a 52 week low of $18.53 and a 52 week high of $51.61. The business's 50-day moving average is $23.07 and its 200-day moving average is $33.58. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the firm earned ($0.56) EPS. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.